Tourmaline Bio https://www.tourmalinebio.com/ Developing Transformative Medicines Thu, 14 Aug 2025 17:53:07 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.3 Senior Director, Assistant General Counsel, Corporate & Securities https://www.tourmalinebio.com/senior-director-assistant-general-counsel-corporate-securities/ Fri, 08 Aug 2025 20:28:45 +0000 https://www.tourmalinebio.com/?p=745 Reports To: Chief Business Officer and General Counsel Functional Area: Legal Position Location: Remote (possible hybrid) Exempt/Non-Exempt: Exempt About Tourmaline Bio, Inc. We are a late-stage clinical biotechnology company with a nimble, driven and accomplished team of entrepreneurs, physicians, and industry experts on a mission to develop transformative medicines that establish new standards of care […]

The post Senior Director, Assistant General Counsel, Corporate & Securities appeared first on Tourmaline Bio.

]]>
Reports To: Chief Business Officer and General Counsel

Functional Area: Legal

Position Location: Remote (possible hybrid)

Exempt/Non-Exempt: Exempt

About Tourmaline Bio, Inc.

We are a late-stage clinical biotechnology company with a nimble, driven and accomplished team of entrepreneurs, physicians, and industry experts on a mission to develop transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases. Our core values help drive this mission and are the foundation of our company culture: we have a passion for our mission; we believe respect and inclusion are core to the success of our team; we overcome obstacles to deliver results for patients; and we push the envelope.

Our lead asset is pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6.  Excluding ongoing trials, pacibekitug was previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is currently developing pacibekitug in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) as its first two indications, with plans to expand into abdominal aortic aneurysm (AAA) and additional diseases in the future.  In May 2025, Tourmaline announced positive topline results from the ongoing Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease.

More information about Tourmaline and pacibekitug can be found at www.tourmalinebio.com.

General Responsibilities:

Reporting to the Chief Business Officer and General Counsel, the Assistant General Counsel, Corporate & Securities is responsible for a broad range of legal matters, providing guidance to multiple departments within the organization, with a focus on corporate and securities matters facing a Nasdaq-listed public company. The Assistant General Counsel, Corporate & Securities plays a key role in supporting SEC filings, corporate governance, potential M&A transactions, equity compensation issues and other important legal, corporate, and strategic projects.

Responsibilities:

  • Working with Tourmaline Finance and outside counsel, manage key securities and corporate governance activities, including preparation of 10-Ks, 10-Qs, 8-Ks, proxy statements, and other SEC filings and reports
  • Coordinate the planning and execution Tourmaline’s annual stockholders meeting.
  • Advise Tourmaline leadership and key stakeholders on matters related to public company disclosures, stock exchange and SEC interactions, and corporate legal requirements.
  • Assist the Chief Business Officer and General Counsel in certain interactions with the Tourmaline board of directors and committees, including coordinating, preparing, and distributing board/committee materials, meeting agendas, and meeting minutes, and maintaining current, audit-ready records of all board and committee actions.
  • Provide legal support to Tourmaline’s Corporate Development and Finance teams, including review of press releases, call scripts, corporate deck, investor communications, and other public messaging.
  • Provide legal support to Tourmaline’s People, Culture and Compliance (PCC) and Finance teams for all equity-related matters, including stockholder inquiries, equity incentive plans, Rule 10b5-1 trading plans, the administration of Tourmaline’s insider trading policy, and related matters.
  • Working with other members of the Tourmaline Legal Department, provide legal support for potential M&A and business development opportunities.
  • Lead the development, implementation, and ongoing management of Tourmaline’s Enterprise Risk Management (ERM) framework to identify, assess, and mitigate key strategic and operational risks.
  • Serve as the legal reviewer for Tourmaline’s Medical, Legal, and Regulatory (MLR) review process, ensuring materials comply with applicable laws, regulations, and industry standards.
  • Work collaboratively with Tourmaline Finance to support audit readiness and SOX compliance activities.
  • Partner cross-functionally to understand business needs, improve processes, and provide right-sized legal support to enable achievement of corporate goals.
  • Educate new hires and existing employees on public company obligations through formal training and regular touchpoints.
  • Work closely with outside counsel and other advisors on each of the foregoing, as appropriate.  Typically, this will occur if there are in-house bandwidth issues or if outside counsel has particular expertise not possessed in-house at Tourmaline.
  • Provide support for other miscellaneous projects and cross-functional initiatives as needed, contributing to evolving corporate priorities and legal departmental goals.

Education and Licensure:

  • Juris Doctor (J.D.) from an ABA-accredited law school is required.
  • Active license to practice law in good standing in at least one U.S. state is required.

Experience and Attributes:

  • At least 6 years of legal experience at a law firm and/or corporation practicing securities and corporate law.
  • Experience in the pharmaceutical/biotech industry is required.
  • At least 3 years leading in-house corporate and securities activities at a U.S. publicly-traded company is strongly preferred.
  • Knowledge of and familiarity with SEC regulations, the Sarbanes-Oxley Act, Nasdaq listing rules, and other related laws, regulations, and guidelines governing publicly-traded pharmaceutical/biotech companies.
  • Experience advising clients on public company reporting, compliance, and corporate governance matters.
  • Motivated self-starter with a strong work ethic and the ability to work well in a team environment.
  • Excellent writing, oral and presentation skills.
  • Strong attention to detail and ability to meet deadlines.
  • Ability to perform independently in a fast-paced work environment.
  • Strong collaboration and influencing skills and the ability to build relationships and work well at all levels, both inside and outside of Tourmaline.
  • Periodic travel to the Tourmaline office in New York, and other travel related to project meetings and/or team meetings, may be required.

Base Salary Range: $260,000 – $310,000 based on candidate professional experience level.

Note:

This job description is written as a guideline to inform a current or prospective Tourmaline employee of what is or will be generally expected in a given position. The description is not intended to be all-encompassing or limiting in any manner.  Duties and responsibilities other than those listed above may be included as needed.

* * * * *

Tourmaline Bio, Inc. is proud to be an equal opportunity employer. We do not discriminate based upon race, religion, color, national origin, gender (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, status as a protected veteran, status as an individual with a disability, or other protected characteristics under applicable law.

The post Senior Director, Assistant General Counsel, Corporate & Securities appeared first on Tourmaline Bio.

]]>
Vice President & TA Head, Cardiovascular, Medical Research https://www.tourmalinebio.com/vice-president-ta-head-cardiovascular-medical-research/ Fri, 08 Aug 2025 20:27:11 +0000 https://www.tourmalinebio.com/?p=744 Reports To: Senior Vice President, Medical Research Functional Area: Medical Research Position Location: Remote (possible hybrid) Exempt/Non-Exempt: Exempt About Tourmaline Bio, Inc. We are a late-stage clinical biotechnology company with a nimble, driven and accomplished team of entrepreneurs, physicians, and industry experts on a mission to develop transformative medicines that establish new standards of care […]

The post Vice President & TA Head, Cardiovascular, Medical Research appeared first on Tourmaline Bio.

]]>
Reports To: Senior Vice President, Medical Research

Functional Area: Medical Research

Position Location: Remote (possible hybrid)

Exempt/Non-Exempt: Exempt

About Tourmaline Bio, Inc.

We are a late-stage clinical biotechnology company with a nimble, driven and accomplished team of entrepreneurs, physicians, and industry experts on a mission to develop transformative medicines that establish new standards of care for patients with life-altering inflammatory and immune diseases. Our core values help drive this mission and are the foundation of our company culture: we have a passion for our mission; we believe respect and inclusion are core to the success of our team; we overcome obstacles to deliver results for patients; and we push the envelope.

Our lead asset is pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6.  Excluding ongoing trials, pacibekitug was previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is currently developing pacibekitug in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) as its first two indications, with plans to expand into abdominal aortic aneurysm (AAA) and additional diseases in the future.  In May 2025, Tourmaline announced positive topline results from the ongoing Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease.

More information about Tourmaline and pacibekitug can be found at www.tourmalinebio.com.

General Responsibilities:

The Vice President, Medical Research (“VP”) is a core member of the Tourmaline Medical Research team and contributes to devising the overall clinical strategy and formulating clinical development plans for the cardiovascular therapeutic area. The VP owns medical activities within clinical development, including providing medical monitoring and oversight of clinical trials, authoring sections of regulatory documents, supporting pharmacovigilance activities, building relationships with external experts and patient advocacy groups, and writing abstracts and publications with Medical Affairs at Tourmaline and medical writing support.

Responsibilities:

  • Formulate clinical development plans that integrate scientific rationale, clinical need, clinical measurement approaches, statistical rigor, regulatory and payor requirements, and company strategy
  • Lead the design and execution of clinical trials for cardiovascular diseases in collaboration with cross-functional partners
  • Provide medical monitoring and oversight for clinical trials in cardiovascular diseases
  • Support medical evaluation of individual case safety reports, including review of narratives and source documents related to serious adverse events (SAEs) and events of special interest (AESIs)
  • Provide medical insights during the review of periodic reports, signal evaluation reports, and ad-hoc safety reports
  • Chair the Safety Management Committee for their studies, leading the strategic oversight of safety issues and decision-making processes
  • Engage proactively in signal detection and risk management, including analysis and interpretation of safety data trends, and developing risk mitigation strategies
  • Collaborate across all levels in the organization on various cross-functional projects and initiatives
  • Serve as a content expert in the review of abstracts, publications, medical information letters, and other medical documents as needed
  • Provide medical input into regulatory document preparation
  • Lead content development for cardiovascular scientific advisory board meetings
  • Build relationships with key external stakeholders including expert physicians and patient advocacy groups in cardiovascular disease
  • Serve as a cardiovascular subject matter expert for Tourmaline teams
  • Participate in the overall portfolio decision-making for the company

Education and Licensure:

  • M.D. with board certification in internal medicine is required
  • Additional board certification in cardiovascular medicine and/or vascular medicine is preferred

Experience and Attributes:

  • 7+ years of clinical trial experience including 3+ years in industry with experience in cardiovascular outcomes trials
  • Experience with early- and late-stage clinical development programs
  • Extensive knowledge of clinical trial methodology, regulatory and compliance requirements governing clinical trials, and experience in development of clinical strategy and the design of study protocols
  • Ability to run a complex clinical research program with minimal direction
  • Excellent interpersonal skills with ability to develop important relationships with key stakeholders across a variety of disciplines
  • Demonstration of strong leadership and influencing skills with cross-functional and product development teams
  • Excellent literature research and writing skills
  • Ability to effectively communicate project status, science, and strategy to a wide variety of internal audiences
  • Ability to effectively communicate externally through conference presentations, publications, investigator meetings, and regulatory interactions
  • Consistently exhibits high level of integrity, ethics, discretion and judgement
  • Proven ability to deliver on a big vision strategy as well as the willingness to roll up sleeves, get down in the weeds, and multi-task
  • Ability to travel up to 20%

Base Salary Range: $390,000 – $418,000 based on candidate professional experience level.

Note:

This job description is written as a guideline to inform a current or prospective Tourmaline employee of what is or will be generally expected in a given position. The description is not intended to be all-encompassing or limiting in any manner.  Duties and responsibilities other than those listed above may be included as needed.

* * * * *

Tourmaline Bio, Inc. is proud to be an equal opportunity employer. We do not discriminate based upon race, religion, color, national origin, gender (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, status as a protected veteran, status as an individual with a disability, or other protected characteristics under applicable law.

The post Vice President & TA Head, Cardiovascular, Medical Research appeared first on Tourmaline Bio.

]]>
Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis https://www.tourmalinebio.com/effect-of-il-6-inhibition-on-lipoproteina-levels-a-systematic-review-and-meta-analysis/ Wed, 16 Oct 2024 13:59:00 +0000 https://www.tourmalinebio.com/?p=624 The post Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis appeared first on Tourmaline Bio.

]]>
The post Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis appeared first on Tourmaline Bio.

]]>
Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention  https://www.tourmalinebio.com/utilization-of-high-sensitivity-c-reactive-protein-testing-in-primary-and-secondary-ascvd-prevention/ Wed, 16 Oct 2024 13:59:00 +0000 https://www.tourmalinebio.com/?p=625 The post Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention  appeared first on Tourmaline Bio.

]]>
The post Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention  appeared first on Tourmaline Bio.

]]>
Evaluating TOUR006 in Participants with Chronic Kidney Disease and Elevated Hs-CRP: Rationale and Design of the TRANQUILITY Phase 2 Study https://www.tourmalinebio.com/evaluating-tour006-in-participants-with-chronic-kidney-disease-and-elevated-hs-crp-rationale-and-design-of-the-tranquility-phase-2-study/ Thu, 01 Aug 2024 20:45:15 +0000 https://www.tourmalinebio.com/?p=573 The post Evaluating TOUR006 in Participants with Chronic Kidney Disease and Elevated Hs-CRP: Rationale and Design of the TRANQUILITY Phase 2 Study appeared first on Tourmaline Bio.

]]>
The post Evaluating TOUR006 in Participants with Chronic Kidney Disease and Elevated Hs-CRP: Rationale and Design of the TRANQUILITY Phase 2 Study appeared first on Tourmaline Bio.

]]>
Modeling to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL-6 Antibody, for Treatment of Thyroid Eye Disease https://www.tourmalinebio.com/modeling-to-inform-dose-selection-for-a-phase-2b-trial-investigating-tour006-a-fully-human-anti-il-6-antibody-for-treatment-of-thyroid-eye-disease-conference-name-is-association-for-research-in-vis/ Fri, 31 May 2024 20:03:08 +0000 https://www.tourmalinebio.com/?p=555 The post Modeling to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL-6 Antibody, for Treatment of Thyroid Eye Disease appeared first on Tourmaline Bio.

]]>
The post Modeling to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL-6 Antibody, for Treatment of Thyroid Eye Disease appeared first on Tourmaline Bio.

]]>